Blueprint Medicines Co. (NASDAQ:BPMC) Receives $123.83 Average Target Price from Analysts
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, twelve have given a buy recommendation and one […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, twelve have given a buy recommendation and one […]
